SageView Advisory Group
TLX icon

SageView Advisory Group’s Telix Pharmaceuticals TLX Stock Holding History

SageView Advisory Group’s Portfolio TLX Stock Details TLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2
Closed -$15 – 2563
2025
Q4 		$15 Buy
+2
New +$19 ﹤0.01% 2591

Other funds holding TLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Portolan Capital Management
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return
PIC
Portland Investment Counsel Burlington, Ontario, Canada $358M AUM 26.37% 1-Year Est. Return
Private Advisor Group
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
Integrated Wealth Concepts
Integrated Wealth Concepts Waltham, Massachusetts $15.3B AUM 25.33% 1-Year Est. Return
Raiffeisen Bank International
Raiffeisen Bank International Vienna, Austria $8.53B AUM 46.94% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $95.2B AUM 32.92% 1-Year Est. Return

SageView Advisory Group's TLX Position: Q1 2026 in Review

SageView Advisory Group sold out of Telix Pharmaceuticals (TLX) in Q1 2026, closing a stake of 2 shares — an estimated $15 sold.

SageView Advisory Group first reported a position in TLX in Q4 2025 and held it in 1 quarter. The position peaked at $15 in Q4 2025. 39 funds tracked by Wall St. Rank hold TLX as of Q1 2026.

  • SageView Advisory Group reported no remaining Telix Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • SageView Advisory Group sold 2 Telix Pharmaceuticals shares in Q1 2026, an estimated $15.
  • SageView Advisory Group first reported a position in Telix Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • SageView Advisory Group's Telix Pharmaceuticals position peaked at $15 in Q4 2025.
  • 39 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q1 2026.

Based on SageView Advisory Group's 13F filing for Q1 2026, filed 10 Aug 2026.